References
- AccordiniSCorsicoAGBraggionMThe cost of persistent asthma in Europe: an international population-based study in adultsInt Arch Allergy Immunol201316019310122948386
- KlaustermeyerWBChoiSHA perspective on systemic corticosteroid therapy in severe bronchial asthma in adultsAllergy Asthma Proc201637319219827178888
- CanonicaGWSennaGMitchellPDO’ByrnePMPassalacquaGVarricchiGTherapeutic interventions in severe asthmaWorld Allergy Organ J2016914027942351
- MenzellaFLusuardiMMontanariGGaleoneCFacciolongoNZucchiLClinical usefulness of mepolizumab in severe eosinophilic asthmaTher Clin Risk Manag20161290791627354806
- HumbertMBeasleyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy200560330931615679715
- Arcispedale Santa Maria Nuova-IRCCSBronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa (BT-ASMN)2014 Available from: https://clinicaltrials.gov/ct2/show/NCT01839591Accessed June 3, 2017 NLM Identifier: NCT01839591
- FajtMLWenzelSEDevelopment of new therapies for severe asthmaAllergy Asthma Immunol Res20179131427826957
- NormansellRWalkerSMilanSJWaltersEHNairPOmalizumab for asthma in adults and childrenCochrane Database Syst Rev20141CD00355924414989
- BousquetJRabeKHumbertMPredicting and evaluating response to omalizumab in patients with severe allergic asthmaRespir Med200710171483149217339107
- BicknellSChaudhuriRLeeNEffectiveness of bronchial thermoplasty in severe asthma in “real life” patients compared with those recruited to clinical trials in the same centerTher Adv Respir Dis20159626727126307767
- WrightDBTrianTSiddiquiSPhenotype modulation of airway smooth muscle in asthmaPulm Pharmacol Ther2013261424922939888
- MagnanABourdinAPrazmaCMTreatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatmentAllergy20167191335134427087007
- WoodruffPGModrekBChoyDFT-helper type 2-driven inflammation defines major subphenotypes of asthmaAm J Respir Crit Care Med2009180538839519483109
- HasegawaKStollSJAhnJBittnerJCCamargoCAJrPrevalence of eosinophilia in hospitalized patients with asthma exacerbationRespir Med201510991230123226198894
- PepeCFoleySShannonJDifferences in airway remodeling between subjects with severe and moderate asthmaJ Allergy Clin Immunol2005116354454916159622
- OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
- GlaxoSmithKlineOmalizumab to mepolizumab switch study in severe eosinophilic asthma patients2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02654145Accessed July 4, 2016 NLM Identifier: NCT02654145